Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve presses ahead with quarter-point rate rise despite banking turmoil
    • Xi Jinping backs Vladimir Putin on Ukraine but holds out on Russian gas pipeline
    • Bundesbank chief says rate-setters must be ‘more stubborn’ in inflation fight
    • Ukraine hit by drone attacks as Russia accuses Kyiv of targeting Crimea
    • Russia alters oil taxes to capture bigger share of trades above price cap
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • What the takeover of Credit Suisse means for UBS
      • UBS to enter talks with Michael Klein to terminate First Boston deal
      • Indian data reveals Adani empire’s reliance on offshore funding
      • Switzerland bans deferred bonuses for Credit Suisse staff
      • Wry humour, grief and Bear Grylls all on show at Credit Suisse conference
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news: Lindsay Lohan, Jake Paul charged by SEC over Justin Sun crypto scheme
      • Asia investors ‘gobsmacked’ by $17bn Credit Suisse bond wipeout
      • JPMorgan Asset Management chief warns on commercial real estate risks
      • Credit Suisse fallout threatens to halt issuance of risky bank debt
      • Russia alters oil taxes to capture bigger share of trades above price cap
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A hefty shock awaits those who see little difference between Starmer and Sunak
      • It’s unwise to get Trump on a technicality
      • EY, KPMG and the fallout of two accounting scandals
      • Four ways to fix the bank problem
      • Don’t assume that DeSantis is a safe alternative to Trump
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • From SVB to the BBC: why did no one see the crisis coming?
      • Football’s first female super-agent Rafaela Pimenta on dealmaking and discrimination
      • Social media content moderators lead charge for better rights
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The bleak beauty of Death Valley
      • Succession Season 4 puts the Roys on the brink of battle royal — review
      • Pack away the Peloton — Daylesford owner launches luxury health club
      • The kingdom of Sir Michael Kadoorie
      • The delectable daring of Herzog & de Meuron
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jamie Smyth

    US Pharmaceutical Correspondent

    Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

    Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 20 March, 2023
      Pharmaceuticals sector
      Big Pharma lobbies for ‘Chips Act’ style tax breaks

      Companies want incentives to create jobs and stave off competition from China

    • Friday, 17 March, 2023
      InterviewCarl Icahn
      Carl Icahn urges Fed to keep fighting inflation ‘disease’

      Comments by activist investor come ahead of US central bank’s rate-setting meeting next week

    • Tuesday, 14 March, 2023
      Pharmaceuticals sector
      US clinic offers ketamine therapy to treat alcoholism

      UK biotech Awakn licences ‘party drug’ to addiction clinics

    • Monday, 13 March, 2023
      Illumina Inc
      Carl Icahn takes aim at genome sequencer Illumina over Grail deal

      Company’s shares jump after activist investor launches proxy battle

    • Monday, 13 March, 2023
      Pfizer Inc
      Pfizer to buy oncology-focused biotech Seagen for $43bn

      US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity

    • Wednesday, 1 March, 2023
      Drug prices
      Eli Lilly to cut price of insulin drugs by 70%

      Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication

    • Wednesday, 1 March, 2023
      News in-depthReproductive rights
      Access to abortion pills at risk in US as judge weighs ‘unprecedented’ case

      Pharma groups and legal experts fear fallout if Texas court overturns regulatory approval after 23 years

    • Sunday, 26 February, 2023
      Pharmaceuticals sector
      Big Pharma fights patent disclosure demand from investors

      Industry rejects call for transparency over use of strategy that can delay competition from generic medicines

    • Tuesday, 21 February, 2023
      Pfizer Inc
      Pfizer pins hopes on record pipeline to recover from post-Covid hangover

      Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs

    • Monday, 20 February, 2023
      The Big Read
      Fentanyl: America’s struggle to contain a deadly drug

      The potent synthetic opioid is claiming lives in the US at an alarming rate. Campaigners say it is time to call it what it is: a weapon of mass destruction

    • Saturday, 18 February, 2023
      Koch Industries Inc
      Koch Industries’ Texas two-step bankruptcy move challenged

      Cancer sufferer files motion to dismiss bankruptcy of Bestwall unit alleging company is not in financial distress

    • Thursday, 16 February, 2023
      Roe vs Wade
      Demand for morning-after pill rises in US as abortion restrictions spread

      Sales of Plan B emergency contraception jump while those of birth control pills and condoms fall, analysis shows

    • Sunday, 12 February, 2023
      Novo Nordisk AS
      Novo Nordisk apologises for not disclosing sponsorship of anti-obesity training

      Healthcare professionals encouraged to prescribe group’s weight loss drug as part of ‘disguised’ promotional campaign

    • Tuesday, 7 February, 2023
      Health sector
      Illumina boosts spending on US lobbying amid opposition to Grail acquisition

      Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers

    • Tuesday, 7 February, 2023
      FT News Briefing podcast9 min listen
      The jig is up for the Texas two-step

      UK to design ‘digital pound’ that could fend off a future private tech rival

    • Monday, 6 February, 2023
      News in-depthBankruptcy
      Talc ruling a blow to J&J and the ‘Texas two-step’ bankruptcy jig

      Ruling by US court will make companies think twice about using Chapter 11 schemes to handle lawsuits

    • Tuesday, 31 January, 2023
      Pfizer Inc
      Pfizer forecasts weak sales as demand for Covid products slows

      US drugmaker expects revenues of between $67bn and $71bn this year, down from a record

    • Tuesday, 31 January, 2023
      AbbVie Inc
      Blockbuster AbbVie drug Humira to face competition in US for first time

      Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch

    • Monday, 30 January, 2023
      Johnson & Johnson Co Inc
      J&J blocked from using bankruptcy to resolve talcum powder lawsuits

      Ruling from US appeals court casts doubt on future of contentious ‘Texas two-step’ manoeuvre

    • Sunday, 29 January, 2023
      News in-depthIllumina Inc
      Has Illumina taken the wrong path in its Grail quest?

      DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators

    • Sunday, 29 January, 2023
      US police
      Memphis police disband unit connected to death of Tyre Nichols

      Move follows release of video that renewed criticism of US policing tactics

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Sunday, 22 January, 2023
      US opioid epidemic
      US warns overdose crisis will spread overseas without action from China

      White House drugs tsar says Beijing needs to tighten rules on supply of raw materials to make fentanyl

    • Monday, 16 January, 2023
      Bayer AG
      Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe

      German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China

    • Saturday, 14 January, 2023
      News in-depthMergers & Acquisitions
      Pharma and biotech seek cure for industry deal slump

      Executives have funding and strategic need for M&A but few are confident to press ahead

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In